Clinical Research Directory

Real-life-persistence to Antifibrotic Treatments

Sponsor: Boehringer Ingelheim

Summary

This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence rate to AF treatment. Primary objective of the study is to measure the percentage of patients still treated up to 30 months after AF treatment initiation.

Official title: Real-life-Persistence to Antifibrotic Treatments

Key Details

Conditions

Interventions

Locations (1)